Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology

On November 18, 2021 Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, reported that data on BTM-3566, in development for the treatment of hematological malignancies including Diffuse Large B-cell Lymphoma, was selected for an oral presentation at the 63rd Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), being held from December 11- 14, 2021, virtually and in-person in Atlanta (Press release, Bantam Pharmaceutical, NOV 18, 2021, View Source [SID1234595823]). Dr. Adrian Schwarzer, MD, PhD, Hannover Medical School, will present non-clinical research on the activity and mechanism of BTM-3566 a novel, oral compound that targets mitochondrial dynamics leading to cellular stress and tumor cell apoptosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the abstract and oral presentation session are as follows:

Title

BTM-3566, a Novel Activator of the Mitochondrial Stress Response Promotes Robust Therapeutic Responses in Vitro and In Vivo in Diffuse Large B-Cell Lymphoma

Date

Monday, December 13, 2021, 4:00 P.M. ET

Location

Georgia World Congress Center, Room B213-B214, Level 2

Presenter

Adrian Schwarzer, MD, PhD, Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Abstract

Available online at: View Source

Accepted abstracts are currently available in a special online-only issue of Blood, ASH (Free ASH Whitepaper)’s official journal, at View Source

About BTM-3566

BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL). BTM-3566’s anti-cancer mechanism of action is unique and differentiated from other therapeutics, disrupting mitochondrial function in tumor cells to induce apoptosis (cell death). An IND application for BTM-3566 in B-cell malignancies is being completed for submission in Q1 2022.